Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000929638-25-000804·Lind Global Fund II LP
Schedule 13G ownership disclosure
NLS PHARMACEUTICS LTD
Common Shares, par value CHF 0.02 per share · CUSIP: H57830137
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Lind Global Fund II LP
Shares: 59,780 · Class: 4.9%
- Lind Global Partners II LLC
Shares: 59,780 · Class: 4.9%
- EASTON JEFF
Shares: 59,780 · Class: 4.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000929638-25-000804
- Form type
- SCHEDULE 13G/A
- Filer
- Lind Global Fund II LP
- CIK
- CIK 1871665
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership